



BY WILLIAM G. WILKOFF, M.D.

LETTERS FROM MAINE

Weighty Mysteries

Since I had seen her last year, my 5-year-old patient Tiana had gained so much weight that I almost didn't recognize her. I knew that when I looked at her growth curve it would now include a

steep upslope. The change had not caught her mother, Maria, by surprise. Tiana's weight was the first topic of her answer to my usual, "How are things goin'?"

Over the years we had had many discussions about how she might remedy the girls' sleep problems. Now we had a new issue to discuss: impending obesity.

My simplistic understanding of obesity has always been that if someone takes in more packets of energy than are

burned, those packets will accumulate in the body as fat.

One must also account for genetic variation because it is clear that some of us are better at storing fat than others are.

Likewise, two automobiles of the same size may have dramatically different fuel efficiency ratings just because that's the way they were designed and built.

It seems, to those of who were blessed with lean parents, to be such a blatantly

simple concept that we are easily frustrated by other families who "just don't get it."

Which side of my simplistic equation had changed for Tiana?

Suspecting that it was an intake problem, I began to quiz Maria about the family's diet. It continues to be predominantly vegetables and grains, no soda, rare desserts. She admitted that there has been a slight increase in chips and snack food since she and her husband had taken over a mom-and-pop convenience store. But, the amounts didn't sound excessive.

I then began to explore the energy utilization side of the balance sheet.

"How much TV are the girls watching?" Here the answer was significantly different from the year before. The television was now on all the time.

"Why?" It turns out that since taking over the new business, Maria had been so busy keeping the books that she admitted using television as a babysitter. In the past, she would often take them outside and spend a good part of the day playing. But now the girls are full-time couch potatoes.

I told Maria what she had suspected herself: that the inactivity was the major contributor to Tiana's weight gain.

Digging deeper, I asked if there was a way that she could do the bookkeeping in the evening after the girls were asleep. The problem with that solution is that the younger child still sleeps poorly and Maria feels she must lie down with her whenever she wakes. She feels that she can't let her cry because it will interrupt her already sleep-deprived and overworked husband. With evenings consumed by sleep refusal, Maria must steal daytime from the girls to do the books. So we were back to talking about sleep, the same issue that Maria and I had batted around for the last 4 years.

Although growth curves as dramatic as Tiana's are unusual, when they do occur they reopen my eyes to the complexity of the obesity problem.

Sometimes the steep rise in body mass index is the result of a cookie-baking grandmother assuming the full-time daycare responsibilities. In other cases, opportunities for activity are lost and dietary supervision gets lost in the family shuffle.

In any case, obesity is one of those rare situations where my simplistic survival tool fails me.

DR. WILKOFF practices general pediatrics in a multispecialty group practice in Brunswick, Maine. Write to Dr. Wilkoff at our editorial offices (pdnews@elsevier.com).

MAXAIR® AUTOHALER®

(pirbuterol acetate inhalation aerosol)

For Oral Inhalation Only

Brief Summary of Prescribing Information

See Package Insert for Full Prescribing Information

INDICATIONS AND USAGE MAXAIR AUTOHALER is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma. It may be used with or without concurrent theophylline and/or corticosteroid therapy. **CONTRAINDICATIONS** MAXAIR AUTOHALER is contraindicated in patients with a history of hypersensitivity to pirbuterol or any of its ingredients. **WARNINGS** **Cardiovascular:** MAXAIR AUTOHALER, like other inhaled beta adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure and/or symptoms. Although such effects are uncommon after administration of MAXAIR AUTOHALER at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, MAXAIR AUTOHALER, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. **Paradoxical Bronchospasm:** MAXAIR AUTOHALER can produce paradoxical bronchospasm, which can be life threatening. If paradoxical bronchospasm occurs, MAXAIR AUTOHALER should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister or vial. **Use of Anti-Inflammatory Agents:** The use of beta adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids. **Deterioration of Asthma:** Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of MAXAIR AUTOHALER than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. **PRECAUTIONS General:** Since pirbuterol is a sympathomimetic amine, it should be used with caution in patients with cardiovascular disorders, including ischemic heart disease, hypertension, or cardiac arrhythmias, in patients with hyperthyroidism or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines or who have convulsive disorders. Significant changes in systolic and diastolic blood pressure could be expected to occur in some patients after use of any beta adrenergic aerosol bronchodilator. Beta adrenergic agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation. **Information for Patients:** The action of MAXAIR AUTOHALER should last up to five hours or longer. MAXAIR AUTOHALER should not be used more frequently than recommended. Do not increase the dose or frequency of MAXAIR AUTOHALER without consulting your physician. If you find that treatment with MAXAIR AUTOHALER becomes less effective for symptomatic relief, or your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While you are using MAXAIR AUTOHALER, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, tremor or nervousness. If you are pregnant or nursing, contact your physician about use of MAXAIR AUTOHALER. Effective and safe use includes an understanding of the way the medication should be administered. As with all aerosol medications, it is recommended to prime (test) MAXAIR AUTOHALER before using for the first time. MAXAIR AUTOHALER should also be primed if it has not been used in 48 hours. As described in the priming procedure, use the test fire slide to release two priming sprays into the air away from yourself and other people. (See "Patient's Instructions For Use" portion of this package insert). The MAXAIR AUTOHALER actuator should not be used with any other inhalation aerosol canister. In addition, canisters for use with MAXAIR AUTOHALER should not be utilized with any other actuator. **Drug Interactions:** Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects. **Monoamine Oxidase Inhibitors or Tricyclic Antidepressants:** Pirbuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of pirbuterol on the vascular system may be potentiated. **Beta Blockers:** Beta adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as MAXAIR AUTOHALER, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta blockers could be considered, although they should be administered with caution. **Diuretics:** The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics. **Carcinogenesis, Mutagenesis and Impairment of Fertility:** In a 2-year study in Sprague-Dawley rats, pirbuterol hydrochloride administered at dietary doses of 1.0, 3.0, and 10 mg/kg (approximately 3, 10, and 35 times the maximum recommended daily inhalation dose for adults and children on a mg/m² basis) showed no evidence of carcinogenicity. In an 18-month study in mice at dietary doses of 1.0, 3.0, and 10 mg/kg (approximately 2, 5, and 15 times the maximum recommended daily inhalation dose for adults and children on a mg/m² basis) no evidence of tumorigenicity was seen. Reproduction studies in rats administered pirbuterol hydrochloride at oral doses of 1, 3, and 10 mg/kg (approximately 3, 10, and 35 times the maximum recommended daily inhalation dose for adults on a mg/m² basis) revealed no evidence of impaired fertility. Pirbuterol dihydrochloride showed no evidence of mutagenicity in *in vitro* assays and host-mediated microbial (Ames) assays for point mutations and *in vivo* tests for somatic or germ cell effects following acute and subchronic treatment in mice (cytogenetic assays). **Teratogenic Effects - Pregnancy Category C:** Pirbuterol was not teratogenic in rats administered oral doses of 30, 100, and 300 mg/kg (approximately 100, 340, and 1000 times the maximum recommended daily inhalation dose for adults on a mg/m² basis). Pirbuterol was not teratogenic in rabbits administered oral doses of 30 and 100 mg/kg (approximately 200 and 680 times the maximum recommended inhalation dose for adults on a mg/m² basis). However, pirbuterol at an oral dose of 300 mg/kg (approximately 2000 times the maximum recommended daily inhalation dose in adults on a mg/m² basis) caused abortions and fetal death. There are no adequate and well-controlled studies in pregnant women. Pirbuterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Labor and Delivery:** Because of the potential for beta-agonist interference with uterine contractility, use of MAXAIR AUTOHALER for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.

Nursing Mothers: It is not known whether pirbuterol is excreted in human milk. Therefore, MAXAIR AUTOHALER should be used during nursing only if the potential benefit justifies the possible risk to the newborn. **Pediatric Use:** MAXAIR AUTOHALER is not recommended for patients under the age of 12 years because of insufficient clinical data to establish safety and effectiveness. **ADVERSE REACTIONS** The following rates of adverse reactions to pirbuterol are based on single- and multiple-dose clinical trials involving 761 patients, 400 of whom received multiple doses (mean duration of treatment was 2.5 months and maximum was 19 months). The following were the adverse reactions reported more frequently than 1 in 100 patients: **CNS:** nervousness (6.9%), tremor (6.0%), headache (2.0%), dizziness (1.2%). **Cardiovascular:** palpitations (1.7%), tachycardia (1.2%). **Respiratory:** cough (1.2%). **Gastrointestinal:** nausea (1.7%). The following adverse reactions occurred less frequently than 1 in 100 patients and there may be a causal relationship with pirbuterol: **CNS:** depression, anxiety, confusion, insomnia, weakness, hyperkinesia, syncope. **Cardiovascular:** hypotension, skipped beats, chest pain. **Gastrointestinal:** dry mouth, glossitis, abdominal pain/cramps, anorexia, diarrhea, stomatitis, nausea and vomiting. **Ear, Nose and Throat:** smell/taste changes, sore throat. **Dermatological:** rash, pruritus. **Other:** numbness in extremities, alopecia, bruising, fatigue, edema, weight gain, flushing. Other adverse reactions were reported with a frequency of less than 1 in 100 patients but a causal relationship between pirbuterol and the reaction could not be determined: migraine, productive cough, wheezing, and dermatitis.

The following rates of adverse reactions during three-month controlled clinical trials involving 310 patients are noted. The table does not include mild reactions.

PERCENT OF PATIENTS WITH MODERATE TO SEVERE ADVERSE REACTIONS

Reaction	Pirbuterol N=157	Metaproterenol N=153
Central Nervous System		
tremors	1.3%	3.3%
nervousness	4.5%	2.6%
headache	1.3%	2.0%
weakness	.0%	1.3%
drowsiness	.0%	0.7%
dizziness	0.6%	.0%
Cardiovascular		
palpitations	1.3%	1.3%
tachycardia	1.3%	2.0%
Respiratory		
chest pain/tightness	1.3%	.0%
cough	.0%	0.7%
Gastrointestinal		
nausea	1.3%	2.0%
diarrhea	1.3%	0.7%
dry mouth	1.3%	1.3%
vomiting	.0%	0.7%
Dermatological		
skin reaction	.0%	0.7%
rash	.0%	1.3%
Other		
bruising	0.6%	.0%
smell/taste change	0.6%	.0%
backache	.0%	0.7%
fatigue	.0%	0.7%
hoarseness	.0%	0.7%
nasal congestion	.0%	0.7%

Electrocardiograms: Electrocardiograms, obtained during a randomized, double-blind, cross-over study in 57 patients, showed no observations or findings considered clinically significant, or related to drug administration. Most electrocardiographic observations, obtained during a randomized, double-blind, cross-over study in 40 patients, were judged not clinically significant or related to drug administration. One patient was noted to have some changes on the one hour postdose electrocardiogram consisting of ST and T wave abnormality suggesting possible inferior ischemia. This abnormality was not observed on the pre-dose or the six hours postdose ECG. A treadmill was subsequently performed and all the findings were normal. **OVERDOSAGE** The expected symptoms with overdosage are those of excessive beta-stimulation and/or any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Hypokalemia may also occur. As with all sympathomimetic aerosol medication, cardiac arrest and even death may be associated with abuse of MAXAIR AUTOHALER. Treatment consists of discontinuation of pirbuterol together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage. The oral median lethal dose of pirbuterol dihydrochloride in mice and rats is greater than 2000 mg/kg (approximately 3400 and 6800 times the maximum recommended daily inhalation dose for adults on a mg/m² basis).

Note: The indented statement below is required by the Federal government's Clean Air Act for all products containing or manufactured with chlorofluorocarbons (CFC's).

WARNING: Contains trichloromonofluoromethane and dichlorodifluoromethane, substances which harm public health and environment by destroying ozone in the upper atmosphere.

A notice similar to the above WARNING has been placed in the "Patient's Instructions For Use" portion of this package insert under the Environmental Protection Agency's (EPA's) regulations. The patient's warning states that the patient should consult his or her physician if there are questions about alternatives.

This is only a brief summary of important information regarding MAXAIR AUTOHALER. For more information please visit www.maxairautohaler.com or call 1-800-326-0255.

Rx only

Manufactured by
3M Pharmaceuticals
Northridge, CA 91324

Distributed by
Graceway™ Pharmaceuticals, LLC
Bristol, TN 37620

654800

US19 Rev0407-1

LETTERS

Letters in response to articles in PEDIATRIC NEWS and its supplements should include your name and address, affiliation, and conflicts of interest in regard to the topic discussed. Letters may be edited for space and clarity.

Mail: Letters, PEDIATRIC NEWS, 5635 Fishers Lane, Suite 6000, Rockville, MD 20852

Fax: 240-221-4400

E-mail: pdnews@elsevier.com